The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer.

Autor:	Dakir el-H; Center for Cancer Research and Cell Biology, Queen's University, Belfast, UK.; Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, Salamanca, Spain.; Institute of Cancer Therapeutics, University of Bradford, Bradford, UK., Pickard A; Center for Cancer Research and Cell Biology, Queen's University, Belfast, UK., Srivastava K; Center for Cancer Research and Cell Biology, Queen's University, Belfast, UK., McCrudden CM; School of Pharmacy, Queen's University Belfast, Belfast, UK., Gross SR; School of Life and Health Sciences, Aston University, Birmingham, UK., Lloyd S; School of Medicine, Animal Facility, Queen's University Belfast, Belfast, UK., Zhang SD; Northern Ireland Centre for Stratified Medicine, Biomedical Sciences, University of Ulster, UK., Margariti A; Center of Experimental Medicine, Queen's University Belfast, Belfast, UK., Morgan R; Institute of Cancer Therapeutics, University of Bradford, Bradford, UK., Rudland PS; Institute of integrative Biology, University of Liverpool, Liverpool, UK., El-Tanani M; Institute of Cancer Therapeutics, University of Bradford, Bradford, UK.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2018 Oct 09; Vol. 9 (79), pp. 34889-34910. Date of Electronic Publication: 2018 Oct 09 (Print Publication: 2018).
DOI:	10.18632/oncotarget.26175
Abstrakt:	Pimozide, an antipsychotic drug of the diphenylbutylpiperidine class, has been shown to suppress cell growth of breast cancer cells in vitro . In this study we further explore the inhibitory effects of this molecule in cancer cells. We found that Pimozide inhibited cell proliferation in a dose- and time-dependent manner in MDA-MB-231 breast cancer cells and A549 lung cancer cells. Furthermore, we found that Pimozide also promoted apoptosis as demonstrated by cell cycle arrest and induction of double-strand DNA breaks but did not result in any effect in the non-transformed MCF10A breast cell line. In order to shed new lights into the molecular pathways affected by Pimozide, we show that Pimozide downregulated RAN GTPase and AKT at both protein and mRNA levels and inhibited the AKT signaling pathway in MDA-MB-231 breast cancer cells. Pimozide also inhibited the epithelial mesenchymal transition and cell migration and downregulated the expression of MMPs. Administration of Pimozide showed a potent in vivo antitumor activity in MDA-MB-231 xenograft animal model and reduced the number of lung metastases by blocking vascular endothelial growth factor receptor 2. Furthermore, Pimozide inhibited myofibroblast formation as evaluated by the reduction in α-smooth muscle actin containing cells. Thus, Pimozide might inhibit tumor development by suppressing angiogenesis and by paracrine stimulation provided by host reactive stromal cells. These results demonstrate a novel in vitro and in vivo antitumor activity of Pimozide against breast and lung cancer cells and provide the proof of concept for a putative Pimozide as a novel approach for cancer therapy. Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu